DYN•benzinga•
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
Summary
BMO Capital Markets initiates coverage on Dyne Therapeutics with an Outperform rating, an $84 target, and a projected $4.3 billion peak sales for DYNE-101.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 12, 2025 by benzinga